ArticlePlant methods2025
Benefiting from the past: establishing in vitro culture of European beech (Fagus sylvatica L.) from provenance trial trees and seedlings.
Article in Plant methods, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- From molecular decline to regeneration failure: seed aging in European beech (Fagus sylvatica) challenges the conservation of forest reproductive material.Tree physiology · 2026Review
- Genetic transformation and CRISPR/Cas12a-mediated gene editing of European beech (Fagus sylvatica L.) employing a transient protoplast system.Communications biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundEuropean beech (Fagus sylvatica L.) is distributed across diverse climate conditions throughout Europe. Local adaptations, such as drought tolerance, could become crucial for maintaining beech populations facing climate change. In vitro culture offers a promising tool for preserving and propagating valuable genotypes and provides a basis for biotechnological research, although establishing and propagating recalcitrant beech in vitro is difficult. To the best of our knowledge, this study is the first to use beeches from a provenance trial to establish in vitro cultures, aiming to capture a wide genetic spectrum and investigate provenance-specific suitability for in vitro cultivation. In addition, a high-throughput method using seedlings has been developed to increase the success of establishing in vitro cultures of a provenance.
resultsActively growing shoots from 22 field-grown provenances were obtained for in vitro establishment. After 12 weeks, shoot formation on shoot tips and nodal segments was induced in 13 provenances (57%), with success rates ranging from 3 to 80%, significantly influenced by the provenance and sampling date of the branches. Combining one harvest each in February and May resulted in the highest shoot formation rate (18%). However, after two years, stable micropropagation was achieved for a single genotype. In the second approach, whole shoots or shoot tips from seedlings were used for in vitro establishment, achieving shoot formation rates between 38 and 94%. Bacterial contamination during establishment was controlled through antibiotic application. Using culture medium without phytohormones improved initial leaf flush on shoot tips within the first 8 weeks of in vitro culture. Phytohormone-supplemented media were needed for shoot multiplication and prolonged in vitro culture. Cultures of 25 genotypes were maintained for up to two years. The viability of in vitro shoots was maintained by supplementing the medium with FeNaEDTA, MgSO
conclusionWith the technical approaches presented here, we provide starting points for the establishment of beech cultures from various types of starting material, as well as for further method improvement for establishment and long-term cultivation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.